Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues

Delforge, Michel; Bladé, Joan; Dimopoulos, Meletios Α.; Façon, Thierry; Kropff, Martin; Ludwig, Heinz; Palumbo, Antônio; Damme, Philip Van; Miguel, Jesús F. San; Sonneveld, Pieter

doi:10.1016/s1470-2045(10)70068-1

Cited by 199 publications

(158 citation statements)

References 69 publications

Supporting

Mentioning

154

Contrasting

Unclassified

Order By: Relevance

“…If grade 3-4 PN occurs treatment should be discontinued. 74 For patients receiving thalidomide, when grade 2 PN occurs, halving thalidomide dose is an effective strategy; when grade ≥ 3 PN occurs, treatment with thalidomide should be discontinued and may be resumed if PN improves to grade 1 after appropriate dose reduction. 75 …”

Section: Peripheral Neuropathymentioning

confidence: 99%

Management of older adults with multiple myeloma

Palumbo¹,

Mina²

2013

Blood Reviews

Self Cite

View full text Add to dashboard Cite

Two-thirds of patients with multiple myeloma are aged 65 years or more and the prevalence of multiple myeloma in elderly patients is expected to rise in the next future. Patients older than 65 years are usually considered ineligible for transplantation. The introduction of novel agents, such as the immunomodulatory drugs thalidomide and lenalidomide and the proteasome inhibitor bortezomib, combined with conventional chemotherapy, has radically changed the treatment paradigm of elderly patients and improved outcome. A sequential approach, consisting of an induction regimen associated with a high rate of complete response, followed by consolidation/maintenance therapy, induces a profound cytoreduction and delays relapse, thus improving survival. Novel agents associated with reduced-intensity autologous transplant showed to be safe and effective in fit elderly patients. Patients older than 75 years or vulnerable ones are more susceptible to adverse events that negatively affect treatment adherence and outcome. In this setting, less toxic regimens and appropriate dose reductions should be adopted. Here we provide an overview of novel agent-based treatment strategies for elderly patients with multiple myeloma.

show abstract

Section: Peripheral Neuropathymentioning

confidence: 99%

Management of older adults with multiple myeloma

Palumbo¹,

Mina²

2013

Blood Reviews

Self Cite

View full text Add to dashboard Cite

show abstract

“…1 The dose-limiting toxicity of bortezomib is peripheral neuropathy, which frequently requires a dose reduction or treatment discontinuation. [2][3][4] Bortezomib induced peripheral neuropathy (BiPN) differs from pre-existing peripheral neuropathy associated with 10% of untreated MM patients. BiPN, described in detail by Delforge et al, 4 is predominantly sensory, reversible in most cases, and characterized by distal paresthesias, numbness and neuropathic pain.…”

Section: Introductionmentioning

confidence: 99%

Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients

Corthals¹,

Kuiper²,

Johnson³

et al. 2011

Haematologica

View full text Add to dashboard Cite

show abstract

“…1 Two good examples of drugs that have been well studied in causing CPIN are thalidomide and bortezomib, both of which are used to treat multiple myeloma. 2 Treatment duration is a critical factor in the development of thalidomide-induced peripheral neuropathy (TiPN). The median time to onset is usually months but can be sooner with higher doses.…”

Section: Other Agentsmentioning

confidence: 99%